Comparing Oncotelic Therapeutics (OTCMKTS:OTLC) & Zealand Pharma A/S (OTCMKTS:ZLDPF)

Oncotelic Therapeutics (OTCMKTS:OTLC) and Zealand Pharma A/S (OTCMKTS:ZLDPF) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Risk & Volatility

Oncotelic Therapeutics has a beta of -0.34, suggesting that its share price is 134% less volatile than the S&P 500. Comparatively, Zealand Pharma A/S has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Oncotelic Therapeutics and Zealand Pharma A/S, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncotelic Therapeutics	0	0	0	0	0.00
Zealand Pharma A/S	0	7	0	3	2.60

Earnings & Valuation

This table compares Oncotelic Therapeutics and Zealand Pharma A/S”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncotelic Therapeutics	$70,000.00	281.10	$249.28 million	$0.59	0.07
Zealand Pharma A/S	$1.40 billion	2.16	$977.29 million	$13.48	3.12

Zealand Pharma A/S has higher revenue and earnings than Oncotelic Therapeutics. Oncotelic Therapeutics is trading at a lower price-to-earnings ratio than Zealand Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Oncotelic Therapeutics and Zealand Pharma A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncotelic Therapeutics	N/A	183.45%	117.54%
Zealand Pharma A/S	68.82%	41.80%	38.49%

Summary

Zealand Pharma A/S beats Oncotelic Therapeutics on 8 of the 11 factors compared between the two stocks.

About Oncotelic Therapeutics

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies. Oncotelic Therapeutics, Inc. is based in Agoura Hills, California.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.